Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Relay Therapeutics, Inc. (Nasdaq: RLAY) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage precision medicine company focused on small molecule therapies for cancer and genetic disease, Relay Therapeutics uses these filings to report on its financial condition, governance and material developments related to programs such as its PI3Kα inhibitor RLY-2608, also known as zovegalisib.
Among the most frequently referenced documents are current reports on Form 8-K, which Relay Therapeutics files to announce events such as quarterly financial results and changes to its Board of Directors. For example, 8-K filings describe the release of earnings press statements for specific quarters and the appointment of new independent directors, along with related committee assignments and equity compensation terms.
Investors researching RLAY can also use this page to locate periodic reports such as Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which the company cites in its risk factor discussions within press releases. These filings typically contain detailed information on research and development expenses, general and administrative costs, net losses, and risk factors associated with developing clinical-stage programs like RLY-2608 and other pipeline assets.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as results of operations, liquidity, and governance changes. Real-time updates from the EDGAR system ensure that new Relay Therapeutics filings, including future Forms 10-K, 10-Q, 8-K and beneficial ownership or insider transaction reports like Form 4, appear promptly on this page.
By combining the raw SEC documents with AI-generated overviews, this filings page offers a structured view into Relay Therapeutics’ regulatory history, financial reporting and significant corporate events relevant to the RLAY stock.